Plans by China to create a free trade port in Hainan province, which have moved forward swiftly this year, bolster opportunities for the growth of the country’s pharmaceutical industry. They are also likely to lower prices on imports for Chinese consumers who... Read More
Medical research in China involving humans will be subject to ethical reviews to ensure privacy, safety, and fairness, if a draft proposal released by the National Healthcare Commission (NHC) becomes law. The proposal would require research and healthcare institutions to create or... Read More
Low insurance reimbursement rates in Taiwan are discouraging the development of innovative pharmaceutical products, according to a study by Fitch Solutions. Because essential healthcare for all residents of the island nation is covered by a single public system, and hospitals negotiate with... Read More
By December 1, 2021, according to the NMPA’s recent release on new Pharmacological Vigilance Quality Management Standards, Marketing Authorization Holders (MAHs) in China will have new pharmacological vigilance responsibilities. MAHs will need to have a dedicated pharmacovigilance team to deal with risk... Read More
Moving to improve coordination of all aspects of rare disease research and treatment, India has approved its first-ever national policy on the prevention and management of such conditions, which afflict a small percentage of the population and are costly to remedy. The... Read More
To speed the import of key new biologic agents needed to combat public health emergencies, including vaccines to help the body develop immunity to the virus that causes COVID-19, South Korea is cutting the steps required for regulatory approval of the products. The... Read More
A major state-sanctioned political party in China made up primarily of medical and health science researchers is calling for making rare disease treatments eligible for government health insurance reimbursement. The public plea this spring by the Chinese Peasants and Workers Democratic Party... Read More
The cost of the majority of pharmaceuticals sold in Japan will undergo major revisions April 1, when the Ministry of Health, Labor and Welfare (MHLW) sets new prices on more than 69% of drugs marketed in the country. The revisions mean the... Read More
Seeking to better control costs of hospital stays, China is taking steps to adopt a payment classification system batching cases that are clinically similar and are expected to use the same levels of hospital resources into groups for the purposes of determining... Read More
With China ahead of other major global economic powers in its recovery from the COVID-19 pandemic, its biopharmaceutical industry is surging, driven by its increased capacity for research and development, growing investment in the sector from venture capital firms and a series... Read More